Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.3052W HIGH $31.77
Volume
1.73 M
Value Traded
53.83 M
Short % Float
16.86%
+5.69%Week
+13.69%1 Month
-1.99%3 Month
+10.2%6 Month
-17.91%5 Year
-9.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.34 B
EPS (TTM)
0.23
P/E Ratio
117.14
Ent. Value
3.22 B
Total Shares
125.69 M
Float Shares
109.51 M
Insiders
12.88%
Institutions
95.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ARQT Catalyst Timeline
Dated clinical, regulatory and corporate events for Arcutis Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arcutis Biotherapeutics, Inc.
584Total events
6Upcoming
198Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationZORYVEApprovedPresentation
ARRECTOR subanalysis of scalp vs body psoriasis with roflumilast foam 0.3% presented at Fall Clinical
plaque psoriasissource ↗
●Oral PresentationPresentation
Real-world topical corticosteroid treatment patterns survey presented at Fall Clinical
atopic dermatitis, psoriasis, seborrheic dermatitissource ↗
▲Timing GuidanceZORYVEApprovedPresentation
ZORYVE cream 0.15% wins 2026 Marie Claire 'Best Prescription Skin Solution' Award
mild to moderate atopic dermatitis (eczema)source ↗
▲Poster PresentationZORYVEApprovedPresentation
INTEGUMENT-INFANT Phase 2 data presented at EADV Congress (Poster P2401)
atopic dermatitissource ↗
●Poster PresentationPresentation
Targeted literature review on topical corticosteroid adverse events presented at EADV Congress (Poster P2706)
atopic dermatitis, psoriasis, seborrheic dermatitissource ↗
▲Partnership / LicenseCorporate
Arcutis partners with Simone Biles to launch Skin to Believe In awareness campaign
seborrheic dermatitis and atopic dermatitis (eczema)source ↗
▲Quarterly UpdateCorporate
Reported Q2 2026 financial results with net income of $15.0 million
▲FDA Filing AcceptedZORYVEApprovedRegulatory Filing
FDA accepted sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis
atopic dermatitissource ↗
▲Enrollment CompleteZORYVEApprovedTrial
Completed enrollment of Phase 2 trial of ZORYVE foam 0.3% in vitiligo
vitiligosource ↗
●Enrollment UpdateZORYVEApprovedTrial
Continuing enrollment in Phase 2 proof-of-concept study of ZORYVE foam 0.3% in hidradenitis suppurativa
hidradenitis suppurativasource ↗
●Trial InitiationARQ-234Trial
Phase 1a/1b first-in-human study of ARQ-234 in healthy volunteers and adults with atopic dermatitis
atopic dermatitissource ↗
▲Runway Guidance UpdateCorporate
Raised 2026 full-year net product sales guidance to $525M-$540M
▲Partnership / LicenseZORYVEApprovedCorporate
Formed partnership with AI-enabled healthcare platform to streamline ZORYVE access
▲FDA Filing AcceptedZORYVEApprovedRegulatory Filing
FDA accepts sNDA for ZORYVE cream 0.05% for atopic dermatitis in infants down to 3 months
mild to moderate atopic dermatitis in infants aged 3 to 24 monthssource ↗
▲Topline ReadoutZORYVEApprovedClinical Data
Positive topline results from INTEGUMENT-INFANT study
mild to moderate atopic dermatitis in infants aged 3 to 24 monthssource ↗
▲Patent GrantedZORYVEApprovedIP / Competition
Obtained two new U.S. patents including method of use and formulation patents
◆PDUFA DateZORYVEApprovedRegulatory Filing
PDUFA target action date for ZORYVE cream 0.3% sNDA for plaque psoriasis in children ages 2-5
plaque psoriasis in children ages 2-5source ↗
◆Oral PresentationPresentation
Arcutis management to present at Goldman Sachs 47th Annual Global Healthcare Conference
▲FDA ApprovalZORYVEApprovedFDA Decision
FDA approved ZORYVE cream 0.3% for children with plaque psoriasis down to age 2
plaque psoriasissource ↗
●sNDA SubmissionZORYVEApprovedRegulatory Filing
sNDA submitted for ZORYVE cream 0.05% for atopic dermatitis in infants 3-24 months
atopic dermatitissource ↗
▲Enrollment CompleteZORYVEApprovedTrial
Enrollment completed in ZORYVE foam 0.3% MUSE trial in children ages 2-11
plaque psoriasissource ↗
▲Trial InitiationARQ-234Trial
Phase 1a/1b first-in-human study initiated for ARQ-234
atopic dermatitissource ↗
▲Oral PresentationZORYVEApprovedPresentation
Late-breaking presentation of INTEGUMENT-INFANT Phase 2 trial results at AAD 2026
atopic dermatitissource ↗
●Milestone PaymentARQ-234Corporate
$10M milestone payment triggered by first patient dosed in ARQ-234 trial
◆sNDA SubmissionZORYVEApprovedRegulatory Filing
sNDA submission to FDA for ZORYVE cream 0.05% to expand indication to infants down to 3 months with mild to moderate atopic dermatitis
atopic dermatitissource ↗
▲Topline ReadoutZORYVEApprovedClinical Data
Positive topline results from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months
atopic dermatitissource ↗
▲Oral PresentationZORYVEApprovedPresentation
AAD issues strong recommendation for ZORYVE cream in pediatric atopic dermatitis guidelines
pediatric atopic dermatitissource ↗
◆Oral PresentationPresentation
Arcutis management fireside chat at 25th Annual Needham Virtual Healthcare Conference
▲Timing GuidanceZORYVEApprovedPresentation
AAD first-ever pediatric atopic dermatitis guidelines published with strong recommendations for ZORYVE cream 0.05% and 0.15%
mild to moderate atopic dermatitis (pediatric)source ↗
▲Late-BreakerZORYVEApprovedPresentation
Late-breaking podium presentation of Phase 2 INTEGUMENT-INFANT results at AAD 2026
atopic dermatitissource ↗
▲Poster PresentationZORYVEApprovedPresentation
E-poster of pooled analysis from DERMIS-1/2 and ARRECTOR showing consistent benefit across body regions
psoriasissource ↗
◆Oral PresentationZORYVEApprovedPresentation
Late-breaking podium presentation of INTEGUMENT-INFANT Phase 2 trial results for ZORYVE cream 0.05% in infants with atopic dermatitis
atopic dermatitissource ↗
▲Full ResultsZORYVEApprovedClinical Data
Full results from INTEGUMENT-INFANT Phase 2 trial presented
atopic dermatitissource ↗
◆Poster PresentationZORYVEApprovedPresentation
5-minute poster presentation of long-term caregiver-reported outcomes from INTEGUMENT-OLE Phase 3 trial of ZORYVE cream 0.05% in children aged 2-5 years
atopic dermatitissource ↗
▲PublicationZORYVEApprovedPresentation
Publication of long-term safety and efficacy data from INTEGUMENT-OLE in Pediatric Dermatology
mild-to-moderate atopic dermatitis in children ages 2–5source ↗
▲First Patient DosedARQ-234Trial
First participant enrolled in Phase 1a/1b study of ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis
atopic dermatitissource ↗
◆Oral PresentationPresentation
Arcutis management to present at TD Cowen 46th Annual Health Care Conference
▲PublicationZORYVEApprovedPresentation
Full results of INTEGUMENT-OLE published in Pediatric Dermatology
atopic dermatitissource ↗
▲Topline ReadoutZORYVEApprovedClinical Data
Positive topline data for ZORYVE cream 0.05% in infants 3-24 months with atopic dermatitis
atopic dermatitissource ↗
▲FDA Filing AcceptedZORYVEApprovedRegulatory Filing
sNDA accepted for ZORYVE cream 0.3% for plaque psoriasis down to 2 years of age
plaque psoriasissource ↗
●Enrollment UpdateZORYVEApprovedTrial
Enrolling patients in Phase 2 proof-of-concept study of ZORYVE foam 0.3% for hidradenitis suppurativa
hidradenitis suppurativasource ↗
▲Topline ReadoutZORYVEApprovedClinical Data
Positive topline results for ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis
atopic dermatitissource ↗
▲Primary Endpoint MetZORYVEApprovedClinical Data
EASI-75 at Week 4 achieved by 58% of participants
atopic dermatitissource ↗
●Partnership / LicenseZORYVEApprovedCorporate
Termination of promotion agreement with Kowa for ZORYVE
Past FDA Catalysts and PDUFA Decisions
How ARQT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ZORYVE cream 0.05% | sNDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$355M
Pipeline Value
$2.0B
Commercial Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 20%
Small Cap(rank 133 of 660)
Percentile Rank
Arcutis Biotherapeutics, Inc. carries a moderate pipeline score (48/100), with $546M risk-adjusted pipeline value, led by ARQ-234 in Atopic Dermatitis (AD) (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $464M x 4.4 = $2.0B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ZORYVE foam | $229M | $121M | +89.9% |
| ZORYVE cream 0.3% | $138M | $104M | +32.8% |
| ZORYVE cream 0.15% | $89M | $35M | +157.2% |
| ZORYVE cream 0.05% | $5M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARQ-234 Monoclonal antibodyNCT07453602 | Atopic Dermatitis (AD) | Phase 1 | RECRUITING | 125 | Apr 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARQT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZORYVE BreakthroughPriorityFast Track+1 | atopic dermatitis | Phase 2 | 2026-10-09 | treatment population: 101 infants; serious adverse events: no serious adverse events; application site irritation: no evidence of application-site irritation for at least 97.9% of infants; completion population: 96 infants; v IGA AD success: 34.4%Read More | Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Larry Todd EdwardsFormer Officer | Sell | 341,980 | $25.00 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARQT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.6 % (-6.7 %) | 258.91 M | 9.87 M |
ARQT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARQT ranks across every disease it competes in
Competitive Position is a premium feature
See how ARQT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARQT News
ARQT▲ +8.5%on this news
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis Biotherapeutics presented new data on ZORYVE (roflumilast) at the EADV Congress and Fall Clinical Dermatology Conference. The findings include positive results from the Phase 2 INTEGUMENT-INFANT trial for infants with atopic dermatitis and analyses from Phase 3 trials showing efficacy in psoriasis. Additionally, real-world research highlighted concerns about long-term corticosteroid use.
Read more →ARQTArcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics announced that its ZORYVE® (roflumilast) cream has won the 2026 Marie Claire Beauty Award for 'Best Prescription Skin Solution.' This award recognizes ZORYVE as a significant innovation in treating mild to moderate atopic dermatitis, marking it as the first prescription medication to receive this honor. The cream is noted for its effectiveness and safety profile, contributing to its status as a leading treatment in dermatology.
Read more →ARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics has granted 62,500 restricted stock units to six new employees as part of its 2022 Inducement Plan. This grant, approved by the Compensation Committee, is intended to incentivize new hires and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, contingent on continued employment.
Read more →ARQTSimone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Simone Biles has partnered with Arcutis to launch the Skin to Believe In campaign, aimed at raising awareness of seborrheic dermatitis and eczema. The campaign encourages individuals to discuss long-term, steroid-free treatment options with healthcare providers. Biles shares her personal experience managing these conditions using ZORYVE, a leading topical therapy. The campaign highlights the importance of addressing chronic skin issues and finding effective solutions.
Read more →ARQTArcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14-16, 2026. The company's management will engage in a fireside chat on September 16 at 1:50 p.m. ET. The event will be accessible via webcast, with a replay available for 180 days.
Read more →ARQTArcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Arcutis Biotherapeutics reported a strong second quarter for 2026, with ZORYVE net product revenues reaching $129.9 million, marking a 59% increase year-over-year. The company raised its full-year sales guidance to $525-$540 million and received FDA approval to expand ZORYVE's indication for young children. Additionally, they completed enrollment for a Phase 2 trial of ZORYVE foam for vitiligo, with results expected in Q4 2026.
Read more →ARQTArcutis Expands Board of Directors with Appointment of Chris Peetz
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors, effective July 15, 2026. Peetz, a seasoned biopharmaceutical executive, is expected to enhance the company's strategic direction, particularly in expanding the ZORYVE franchise. His previous experience includes leadership roles at Mirum Pharmaceuticals and Flashlight Therapeutics, indicating a strong background in the industry.
Read more →ARQTArcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Arcutis Biotherapeutics, Inc. announced it will report its second quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Arcutis focuses on innovations in immuno-dermatology and has developed a strong portfolio of treatments for chronic inflammatory skin diseases.
Read more →ARQTFDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months. The application is supported by positive results from clinical studies. The FDA has set a target action date of February 23, 2027, for potential approval.
Read more →ARQTArcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Arcutis Biotherapeutics has launched a new virtual health platform aimed at enhancing access to care for individuals suffering from chronic inflammatory skin diseases such as eczema, seborrheic dermatitis, and plaque psoriasis. This platform connects patients with board-certified dermatologists for evaluations and treatment discussions, complementing traditional in-office care. The initiative is designed to address barriers to dermatology access and support timely treatment options, including the use of ZORYVE.
Read more →ARQTFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
The FDA has approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) cream 0.3% for treating plaque psoriasis in children as young as 2 years old. This marks the first steroid-free, once-daily topical treatment for this age group. The approval is based on clinical studies demonstrating its safety and efficacy, filling a critical gap in pediatric psoriasis care.
Read more →ARQTNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Arcutis Biotherapeutics announced the publication of a new manuscript by the Genital Psoriasis Wellness Consortium in the American Journal of Clinical Dermatology. This document offers expert-driven, age-specific guidance for diagnosing and managing genital psoriasis, which affects a significant portion of individuals with plaque psoriasis. The recommendations aim to improve clinician awareness and patient care across different age groups.
Read more →ARQTArcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami. The company's participation includes a fireside chat on June 9, 2026. Arcutis is engaged in developing innovative dermatological treatments, addressing the needs of those with immune-mediated skin conditions. The company highlights its advanced targeted topicals that treat major inflammatory skin diseases.
Read more →ARQTArcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Arcutis Biotherapeutics reported strong Q1 2026 financial results, with net product revenues for ZORYVE reaching $105.4 million. This reflects a substantial year-over-year increase of 65%, although there was a 17% decline from the previous quarter. The company has made strides in its pipeline, including the submission of a supplemental NDA to expand the indication for ZORYVE and the initiation of a Phase 1 clinical trial for ARQ-234. Despite the positive revenue growth, the company faced increased R&D expenses and a sequential decline in sales.
Read more →ARQTArcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Arcutis Biotherapeutics has submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.05%, aiming to expand its use to treat mild to moderate atopic dermatitis in infants as young as 3 months. The submission is backed by positive results from the INTEGUMENT-INFANT Phase 2 study, which demonstrated the cream's safety and efficacy. If approved, this treatment could provide a vital non-steroidal option for infants facing limited therapeutic choices.
Read more →About Arcutis Biotherapeutics, Inc.
Headquarters3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA, 91361
Founded2016
BIOPHARMAWATCH ELITE PLUS
Trade the next ARQT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime